Samelisant

From WikiMD's Medical Encyclopedia

Revision as of 06:22, 5 March 2025 by Prab (talk | contribs) (CSV import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

A histamine H3 receptor antagonist/inverse agonist


Chemical structure of Samelisant

Samelisant is a pharmaceutical compound that acts as a histamine H3 receptor antagonist and inverse agonist. It is primarily investigated for its potential therapeutic applications in the treatment of narcolepsy and other sleep disorders.

Pharmacology[edit]

Samelisant functions by targeting the histamine H3 receptor, which is predominantly found in the central nervous system. The H3 receptor is involved in the regulation of the release of various neurotransmitters, including histamine, dopamine, norepinephrine, and acetylcholine. By antagonizing and inversely agonizing this receptor, Samelisant increases the release of these neurotransmitters, which can enhance wakefulness and cognitive function.

Mechanism of Action[edit]

The mechanism of action of Samelisant involves its binding to the histamine H3 receptor, where it acts as an antagonist and inverse agonist. This dual action results in the blockade of the receptor's normal inhibitory function on neurotransmitter release, leading to increased levels of histamine and other neurotransmitters in the brain. This increase is thought to contribute to its wake-promoting and cognitive-enhancing effects.

Therapeutic Applications[edit]

Samelisant is being studied for its potential use in treating narcolepsy, a chronic sleep disorder characterized by excessive daytime sleepiness and sudden loss of muscle tone (cataplexy). By promoting wakefulness, Samelisant may help alleviate some of the symptoms associated with narcolepsy. Additionally, its effects on neurotransmitter release suggest potential applications in other conditions involving cognitive dysfunction and sleep disturbances.

Development and Research[edit]

Research into Samelisant is ongoing, with clinical trials being conducted to evaluate its efficacy and safety in humans. These studies aim to determine the optimal dosing regimen and to identify any potential side effects associated with its use. The development of Samelisant is part of a broader effort to create new treatments for sleep disorders and cognitive impairments.

Related pages[edit]

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.